Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Among authors: anderson k. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Thalidomide: emerging role in cancer medicine.
Richardson P, Hideshima T, Anderson K. Richardson P, et al. Among authors: anderson k. Annu Rev Med. 2002;53:629-57. doi: 10.1146/annurev.med.53.082901.104043. Annu Rev Med. 2002. PMID: 11818493 Review.
Thalidomide in multiple myeloma.
Richardson P, Hideshima T, Anderson K. Richardson P, et al. Among authors: anderson k. Biomed Pharmacother. 2002 May;56(3):115-28. doi: 10.1016/s0753-3322(02)00168-3. Biomed Pharmacother. 2002. PMID: 12046682 Review.
Proteasome inhibition in hematologic malignancies.
Richardson PG, Hideshima T, Mitsiades C, Anderson K. Richardson PG, et al. Among authors: anderson k. Ann Med. 2004;36(4):304-14. doi: 10.1080/07853890410030877. Ann Med. 2004. PMID: 15224657 Review.
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, Patin J, Knight R, Zeldis J, Dalton W, Anderson K. Richardson P, et al. Among authors: anderson k. Mayo Clin Proc. 2004 Jul;79(7):875-82. doi: 10.4065/79.7.875. Mayo Clin Proc. 2004. PMID: 15244383 Clinical Trial.
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Berenson JR, et al. Among authors: anderson k. Cancer. 2005 Nov 15;104(10):2141-8. doi: 10.1002/cncr.21427. Cancer. 2005. PMID: 16206291 Free article. Clinical Trial.
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Richardson PG, Schlossman R, Mitsiades C, Hideshima T, Munshi N, Anderson K. Richardson PG, et al. Among authors: anderson k. Clin Lymphoma Myeloma. 2005 Sep;6(2):84-8. doi: 10.3816/CLM.2005.n.033. Clin Lymphoma Myeloma. 2005. PMID: 16231845 Review.
8,130 results